EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	709	(514/252.13,514/255.01,514/255. 05,544/358,544/360,544/367, 544/372,544/374,544/386).CCLS.	US-PGPUB; USPAT	OR	OFF	2007/04/19 18:20
L2	.0	l1 and piperazinylacylpiperidine	US-PGPUB; USPAT	OR	ON	2007/04/19 18:21
L3	99	l1 and piperazinyl and acyl and piperidine	US-PGPUB; USPAT	OR	ON	2007/04/19 18:21
L4	0	l1 and piperazinylpiperidine	US-PGPUB; USPAT	OR	ON	2007/04/19 18:21
L5	0	I1 and piperazinylacyl and piperidine	US-PGPUB; USPAT	OR	ON	2007/04/19 18:22
L6	150	l1 and piperazine and acyl and piperidine	US-PGPUB; USPAT	OR	ON	2007/04/19 18:22
L7	1	I1 and piperazine and acyl and piperidine and ketone and 1, 3-thiazol-2-yl	US-PGPUB; USPAT	OR	ON	2007/04/19 18:26
L8	1	l1 and piperazine and piperidine and 1,3-thiazol-2-yl	US-PGPUB; USPAT	OR	ON	2007/04/19 18:26

40/513682 10/516,808

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: SSPTAEAL1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Web Page URLs for STN Seminar Schedule - N. America
NEWS
                 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS
         JAN 08
     2
                 CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS
     3
         JAN 16
                 IPC version 2007.01 thesaurus available on STN
NEWS 4
         JAN 16
NEWS 5
         JAN 16
                 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6
        JAN 22
                 CA/CAplus updated with revised CAS roles
NEWS 7
         JAN 22
                 CA/CAplus enhanced with patent applications from India
NEWS 8
         JAN 29
                 PHAR reloaded with new search and display fields
NEWS 9
         JAN 29
                 CAS Registry Number crossover limit increased to 300,000 in
                 multiple databases
NEWS 10
         FEB 15
                 PATDPASPC enhanced with Drug Approval numbers
NEWS 11
         FEB 15
                 RUSSIAPAT enhanced with pre-1994 records
NEWS 12 FEB 23
                 KOREAPAT enhanced with IPC 8 features and functionality
                 MEDLINE reloaded with enhancements
NEWS 13 FEB 26
                 EMBASE enhanced with Clinical Trial Number field
NEWS 14 FEB 26
                 TOXCENTER enhanced with reloaded MEDLINE
NEWS 15
        FEB 26
                 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 16
         FEB 26
NEWS 17
         FEB 26
                 CAS Registry Number crossover limit increased from 10,000
                 to 300,000 in multiple databases
                 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 18
         MAR 15
NEWS 19
         MAR 16
                 CASREACT coverage extended
NEWS 20
         MAR 20
                 MARPAT now updated daily
         MAR 22
                 LWPI reloaded
NEWS 21
NEWS 22
         MAR 30
                 RDISCLOSURE reloaded with enhancements
                 INPADOCDB will replace INPADOC on STN
NEWS 23
         MAR 30
NEWS 24
         APR 02
                 JICST-EPLUS removed from database clusters and STN
```

NEWS HOURS STN Operating Hours Plus Help Desk Availability NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),

NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT

AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

NEWS EXPRESS

FILE 'HOME' ENTERED AT 17:03:46 ON 19 APR 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 17:04:22 ON 19 APR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2007 HIGHEST RN 930838-51-0 DICTIONARY FILE UPDATES: 18 APR 2007 HIGHEST RN 930838-51-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> Uploading C:\Program Files\Stnexp\Queries\10516808.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:04:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5 TO 23

PROJECTED ITERATIONS: 5 TO 234
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s 11 full

FULL SEARCH INITIATED 17:04:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 176 TO ITERATE

100.0% PROCESSED 176 ITERATIONS 15 ANSWERS

SEARCH TIME: 00.00.01

L3 15 SEA SSS FUL L1

=> file capls

'CAPLS' IS NOT A VALID FILE NAME SESSION CONTINUES IN FILE 'REGISTRY'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION 172.10 172.31

FILE 'CAPLUS' ENTERED AT 17:04:59 ON 19 APR 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Apr 2007 VOL 146 ISS 17 FILE LAST UPDATED: 18 Apr 2007 (20070418/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.

They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 13 full

1 L3 L4

=> d ibib abs hitstr

L4ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:991507 CAPLUS

DOCUMENT NUMBER: 140:42206

Preparation of piperazinylacylpiperidines as TITLE:

inhibitors of NGF binding (nerve growth factor) to p75NTR (p75 neurotrophic) receptor for treating p75NTR

related diseases

Bono, Francoise; Bosch, Michaeel; Dos Santos, Victor; INVENTOR(S):

Herbert, Jean Marc; Nisato, Dino; Tonnerre, Bernard;

Wagnon, Jean

Sanofi-Synthelabo, Fr. PATENT ASSIGNEE(S): SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent French

LANGUAGE: FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PA'	PATENT NO.								APPLICATION NO.					DATE					
WO	WO 2003104226						A1 20031218			WO 2003-FR1686					20030605				
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	ВG,	BR,	BY,	ΒZ,	CA,	CH,	CN,		
							DK,												
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	LK,	LR,		
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NI,	NO,	NZ,	OM,		
		PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	ТJ,	TM,	TN,	TR,	TT,		
		TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW							
	RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,		
		KG,	KZ,	MD,	RU,	TJ,	TM,	AΤ,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,		
		FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,		
		BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG		
AU	AU 2003255645					20031222 AU 2003-255645					45	20030605							
EP	EP 1513836			A 1		2005	050316 EP 2003-757109					09	20030605						
EP	1513	836			В1		2006	0503											
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	ΝL,	SE,	MC,	PT,		
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK			
	CN 1675203					20050928			CN 2003-818808				20030605						
JP	JP 2005533051																		
AT	AT 325122					20060615 AT 2003-757109					09	20030605							
AT	AT 336491									AT 2003-757108									
PT	PT 1513836								PT 2003-757109				20030605						
	ES 2264001								ES 2003-3757109										
US	US 2006167007					L 20060727			US 2004-516808										
PRIORIT	PRIORITY APPLN. INFO.:										002-			_	-	0020			
										WO 2	003-	FR16	86	1	₩ 2	0030	605		

OTHER SOURCE(S):

MARPAT 140:42206

GI

$$R^{2}$$
 $N-C-Y-N$
 $N-R^{4}$
 R^{3}

$$V_{HO}$$

N-C-CH₂-N

N

S

II

AB Title compds. I [wherein: Y = (CH2)n; n = 1 or 2; R1 = halo, CF3, alkyl, alkoxy, trifluoromethoxy; R2 = H, halo; R3 = H, OR5, CH2OR5, NH2 and derivs., NHCOR6 and derivs., NHCONH2 and derivs., CH2NR7R8, CH2NHCONH2 and derivs., alkoxycarbonyl, CONH2 and derivs.; or R3 forms a double bond between the carbon atom where it is bound to and the neighboring carbon atom of the piperidine cycle; R4 = 1,3-thiazol-2-yl; R5 = H, alkyl, alkylcarbonyl; R6 = alkyl, (CH2)mNH2 and derivs.; m = 1,2, or 3; R7, R8 = independently H, alkyl; R8 = (CH2)qOH, (CH2)qSMe; q = 2 or 3; or R7R8N = aziridine, azetidine, pyrrolidine, piperidine, morpholine; and their salts, hydrates and solvates] were prepared as inhibitors of the binding of 125I NGF to p75NTR (p75 neurotrophic) receptor and of the apoptosis induced by NGF (nerve growth factor) for treating p75NTR related diseases (no data). For example, I (m.p. = 157-158°) was prepared by reacting 2-chloro-1-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-1ethanone (preparation given) and 1-(1,3-thiazol-2-yl)piperazine dihydrochloride (preparation given) in the presence of KI/K2CO3/MeCN. I inhibited the binding of 1251 NGF to p75NTR receptor with IC50 in the range of 10-11 M to 10-6 M at the biochem. level. I inhibited the pro-apoptic effect induced by NGF, via growing cells expressing preferentially p75NTR, with IC50 in the range of 10-11 M to 10-6 M at the cellular level.

IT 634613-42-6P, 1-[4-Hydroxy-4-[3-(trifluoromethyl)phenyl]-1piperidinyl]-2-[4-(1,3-thiazol-2-yl)-1-piperazinyl]-1-ethanone
634613-43-7P 634613-45-9P, 1-[4-(Aminomethyl)-4-[3(trifluoromethyl)phenyl]-1-piperidinyl]-2-[4-(1,3-thiazol-2-yl)-1piperazinyl]-1-ethanone Trihydrochloride
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(NGF binding inhibitor; preparation of piperazinylacylpiperidines as NGF
binding inhibitors to p75NTR receptor and of the apoptosis induced by
NGF)

RN 634613-42-6 CAPLUS

CN 4-Piperidinol, 1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

RN 634613-43-7 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]-4[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & O & \\
 & N \\
 & N \\
 & S \\
\end{array}$$

$$\begin{array}{c|c}
 & O \\
 & N \\
\end{array}$$

$$\begin{array}{c|c}
 & CF_3 \\
\end{array}$$

RN 634613-45-9 CAPLUS

CN 4-Piperidinemethanamine, 1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-, trihydrochloride (9CI) (CA INDEX NAME)

●3 HCl

IT 634613-37-9P 634613-38-0P 634613-39-1P
634613-40-4P 634613-41-5P 634613-44-8P,
2-[4-(1,3-Thiazol-2-yl)-1-piperazinyl]-1-[4-[3-(trifluoromethyl)phenyl]3,6-dihydro-1-(2H)-pyridinyl]-1-ethanone dioxalate 634613-47-1P,
1-[4-[(Dimethylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]2-[4-(1,3-thiazol-2-yl)-1-piperazinyl]-1-ethanone 634613-48-2P,
1-[4-[(Methylamino)methyl]-4-[3-(trifluoromethyl)phenyl]-1-piperidinyl]-2[4-(1,3-thiazol-2-yl)-1-piperazinyl]-1-ethanone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(NGF binding inhibitor; preparation of piperazinylacylpiperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)

RN 634613-37-9 CAPLUS

CN 4-Piperidinol, 4-[4-chloro-3-(trifluoromethyl)phenyl]-1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 634613-38-0 CAPLUS

CN 4-Piperidinol, 4-(3-methoxyphenyl)-1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & &$$

RN 634613-39-1 CAPLUS

CN 4-Piperidinol, 4-(3-methylphenyl)-1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ &$$

RN 634613-40-4 CAPLUS

CN Piperidine, 4-methoxy-1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ &$$

● HCl

RN 634613-41-5 CAPLUS

CN 4-Piperidinol, 1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & \text{HO} \\
 & \text{N} \\
 & \text{N}
\end{array}$$

$$\begin{array}{c|c}
 & \text{N} \\
 & \text{CH}_2 - \text{C} \\
 & \text{N}
\end{array}$$

$$\begin{array}{c|c}
 & \text{O} \\
 & \text{O} \\
 & \text{O}
\end{array}$$

RN 634613-44-8 CAPLUS

CN Pyridine, 1,2,3,6-tetrahydro-1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 634613-43-7

CMF C21 H23 F3 N4 O S

$$CF_3$$

CM 2

CRN 144-62-7

CMF C2 H2 O4

RN 634613-47-1 CAPLUS

CN 4-Piperidinemethanamine, N,N-dimethyl-1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

$$CF_3$$

$$CH_2-NMe_2$$

$$N-CH_2-C-N$$

RN 634613-48-2 CAPLUS

CN 4-Piperidinemethanamine, N-methyl-1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

IT 634613-46-0P, 1-[2-[4-(1,3-Thiazol-2-yl)-1-piperazinyl]acetyl]-4[3-(trifluoromethyl)phenyl]-4-piperidinecarbonitrile 634613-49-3P
, tert-Butylmethyl [1-[2-[4-(1,3-thiazol-2-yl)-1-piperazinyl]-1-oxoethyl]4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]methylcarbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of piperazinylacylpiperidines as NGF binding inhibitors to p75NTR receptor and of the apoptosis induced by NGF)

RN 634613-46-0 CAPLUS

CN 4-Piperidinecarbonitrile, 1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
N & N \\
N & N \\
S & N
\end{array}$$

$$\begin{array}{c|c}
N & NC \\
CF_3 \\
\end{array}$$

RN 634613-49-3 CAPLUS

CN Carbamic acid, methyl[1-[[4-(2-thiazolyl)-1-piperazinyl]acetyl]-4-[3-(trifluoromethyl)phenyl]-4-piperidinyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

2

REFERENCE COUNT:

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT